Alpha-fetoprotein (AFP), as the name implies, was first detected in pregnant women and produced by proliferating active fetal cells. It was later found to have a certain connection with proliferating active liver cancer cells, so it is used as a screening indicator for early liver cancer (especially for patients with cirrhosis). I. Performance of hepatocellular carcinoma alpha-fetoprotein (AFP) 1. Positive rate of alpha-fetoprotein (AFP) in hepatocellular carcinoma patients: about 70-90%, if combined with imaging such as obvious reinforcement rules on CT and history of combined hepatitis B cirrhosis, it can clinically diagnose hepatocellular carcinoma, with accuracy rate of about 98%. 2, cirrhotic patients with elevated alpha-fetoprotein (AFP): combined with enhanced CT to have a clear diagnostic significance, otherwise pregnancy, liver inflammation (liver damage in the repair process, hepatocytes are also proliferating actively, but usually below 400-800, a few may exceed 1000) may be elevated 2, liver cancer alpha-fetoprotein (AFP) description 1 The pseudo elevation of AFP in patients with cirrhosis is temporary. After antiviral treatment, hepatitis will turn from active to chronic stage, and AFP will drop naturally. If this high level is increasing from time to time, it must be alarmed, such as ultrasound and CT enhancement. 2. For patients with high AFP before liver cancer surgery, postoperative AFP can be used as an indicator for regular monitoring whether tumor recurrence. Sometimes ultrasound or CT has not yet detected liver recurrence, but metastatic lesions in lung, bone, or even brain, adrenal gland and other places in the body will secrete AFP. It is recommended that lung ct plus liver enhancement ct, also consider pet examination (only some large tertiary hospitals, such as the First Affiliated Hospital of Zhejiang University, Zhongshan Hospital of Fudan University, etc.; each time about 10,000 yuan, not into the medical insurance) 3, the significance of frequent review, is to find those “bad eggs” waking up from sleep, to give timely The purpose of frequent rechecking is to detect the bad eggs that wake up from their slumber and give timely treatment. However, for patients with liver cancer whose preoperative AFP is not high (indeed, 10-30% of liver cancer patients have low preoperative AFP), they may lose a way to monitor recurrence, and it is recommended to monitor recurrence with the help of regular recurrent ultrasound or even enhanced CT. Alpha-fetoprotein (AFP) plays an important role in the diagnosis of liver cancer. However, the diagnosis of hepatocellular carcinoma should not be based on the elevation of AFP alone. AFP is a special protein contained in human blood during embryonic period, which is synthesized by ribose particles in the rough endoplasmic reticulum of hepatocytes. In addition to hepatocellular carcinoma, it can also be increased in pregnancy, embryonal carcinoma such as testicular carcinoma, ovarian carcinoma and very few cancers of stomach, pancreas, bile duct and colorectum, but its absolute value is not as high as hepatocellular carcinoma. Elevated serum AFP is the most important marker of hepatocellular carcinoma, with a positive rate of 60-70%. If serum AFP is consistently greater than 400ng/ml for more than 4 weeks and transaminases are normal, liver cancer should be highly suspected. However, elevated AFP alone cannot confirm the diagnosis of hepatocellular carcinoma and cannot make the diagnosis of hepatocellular carcinoma, because there are variants of AFP, which can also be elevated in patients with non-hepatocellular carcinoma. For non-cancerous liver disease, elevated AFP can be identified with the help of AFP variants. Elevated cutin A-conjugated AFP can be seen in hepatocellular carcinoma and cirrhosis, elevated cutin M unconjugated AFP is seen in embryonal carcinoma and hepatocellular carcinoma, and elevated lentil agglutinin unconjugated AFP is seen in chronic hepatitis and cirrhosis. Elevated lentil agglutinin-binding alpha-fetoprotein (AFP) is most often seen in hepatocellular carcinoma.